Literature DB >> 11529718

Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.

G Xu1, T L Loftus, H Wargo, J A Turpin, R W Buckheit, M Cushman.   

Abstract

The Sonogashira and Stille cross-coupling reactions have been employed in the synthesis of several non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the alkenyldiarylmethane (ADAM) series. The synthesis has been carried out both in solution and on a solid support. In contrast to previous syntheses of NNRTIs in the ADAM series, the present strategy allows the incorporation of differently substituted aromatic rings in a stereochemically defined fashion. The most potent of the new ADAMs inhibited the cytopathic effect of HIV-1RF in CEM-SS cell culture with an EC50 value of 20 nM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11529718     DOI: 10.1021/jo0100291

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  5 in total

1.  Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Bo-Liang Deng; Tracy L Hartman; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Phillip E Fanwick; Mark Cushman
Journal:  J Med Chem       Date:  2005-09-22       Impact factor: 7.446

2.  Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.

Authors:  Takeshi Sakamoto; Matthew D Cullen; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Journal:  J Med Chem       Date:  2007-06-19       Impact factor: 7.446

3.  Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Bo-Liang Deng; Yujie Zhao; Tracy L Hartman; Karen Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Journal:  Eur J Med Chem       Date:  2008-09-19       Impact factor: 6.514

4.  Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.

Authors:  Matthew D Cullen; William C Ho; Joseph D Bauman; Kalyan Das; Eddy Arnold; Tracy L Hartman; Karen M Watson; Robert W Buckheit; Christophe Pannecouque; Erik De Clercq; Mark Cushman
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

Review 5.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.